Answers are grounded in this paper and cite their sources.
INTRODUCTION: Sutimlimab, a C1s inhibitor, is the only agent approved for hemolysis in cold agglutinin disease (CAD). Its evidence base has expanded through extensions, access programs, and registries that may re-report patients. We conducted a systematic review linking reports into independent cohorts before synthesis. METHODS: MEDLINE, EMBASE, CENTRAL, ClinicalTrials.gov and Google Scholar were searched to August 2026. Adults with primary CAD receiving sutimlimab were eligible. Reports were linked into cohorts and overlap quantified. Outcomes were pooled using Bayesian random-effects models. Risk of bias was assessed using RoB 2 and ROBINS-I, and certainty using GRADE. RESULTS: Twenty-two reports described eight cohorts comprising 239 unique patients; 17 patients appeared more than once, and further undocumented overlap could not be excluded. Pooled mean hemoglobin increase was 2.53 g/dL (95% CrI 1.97-3.15; 4 cohorts), hemoglobin response 68.1% (51.2-81.7; 3 cohorts), and transfusion avoidance 81.1% (67.8-89.6; 3 cohorts). Hemolysis recurred after discontinuation in every cohort with available data, including after 2 to 4 years of treatment. All non-randomized cohorts were at serious risk of bias; certainty was low to very low. CONCLUSIONS: Sutimlimab consistently controls hemolysis in CAD, although certainty is low, few cohorts contribute to each estimate, and benefit appears contingent on continued treatment. Because sutimlimab reports frequently re-describe the same patients, syntheses in this field should link reports to cohorts before pooling. PROTOCOL REGISTRATION: www.crd.york.ac.uk/prospero identifier CRD420261470297.
No takes yet. Share an insight, caveat, or question.
Reyes et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: